Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
MA05 - Immune Landscape and Molecular Profiling of Lung Cancer
- 15:45 - 16:45
- 8/07/2022
- Location: Hall C8
- Not for CME Credit
- Type: Mini Oral
- Track: Tumor Biology and Biomarkers
- Moderators:Luis Paz-Ares, Tina Cascone
-
+
MA05.08 - MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History
16:17 - 16:22 | Presenter: Jennifer A. Marks
- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-018 - Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression
Presenter: Cole Friedes- Abstract
Loading... -
+
EP08.01-063 - Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%
Presenter: Mohsin Shah- Abstract
Loading...
-
+
P1.15 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 17:00 - 19:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: Regular Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
P1.15-07 - Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
Presenter: Melina Elpi Marmarelis- Abstract
Loading...
-
+
MA07 - Overcoming Resistance to EGFR Inhibitors
- 12:15 - 13:15
- 8/08/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Dana Lucia Stanculeanu, Ross Soo
-
+
MA07.04 - Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
12:22 - 12:27 | Presenter: Melina Elpi Marmarelis
- Abstract
Loading...